Literature DB >> 20377587

Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.

Antonella Poloni, Debora Capelli, Silvia Trappolini, Benedetta Costantini, Mauro Montanari, Guido Gini, Ilaria Scortechini, Giorgia Mancini, Giancarlo Discepoli, Pietro Leoni, Attilio Olivieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20377587     DOI： 10.1111/j.1365-2141.2010.08168.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.

Authors:  Motoshi Ichikawa; Akira Hangaishi; Yasuhito Nannya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-10-28       Impact factor: 2.490

2.  Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.

Authors:  Debora Capelli; Francesco Saraceni; Alessandro Fiorentini; Martina Chiarucci; Diego Menotti; Antonella Poloni; Giancarlo Discepoli; Pietro Leoni; Attilio Olivieri
Journal:  Adv Ther       Date:  2020-04-15       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.